Drug Manufacturers - General · NYSE
Current Price
$286.20
PE Ratio (TTM)
49.1x
Intrinsic Value
$287.27
+0.4% margin of safety
As of 2026-11-20, applying a 49.0x earnings multiple to AbbVie Inc.'s (ABBV) earnings per share of $5.84 yields a fair value estimate of $287.27 per share, versus a market price of $286.2.
Fair value from earnings multiples is sensitive to the multiple you choose. Across the sensitivity grid the estimate spans $248.12 to $331.23. This is a relative estimate anchored to earnings, not a statement of fact. For a cash flow based view, see the intrinsic value estimate on the DCF page.
How the PE model works · Recalculate in PE mode · ABBV intrinsic value (DCF view)
At $286.2, ABBV trades about 0.4% below its PE-based fair value estimate, a modest discount to its earnings power, though not enough to call it cheap outright.
COMPETITIVE MOAT
↑Humira's Legacy and Diversification
AbbVie's strong historical reliance on Humira has built significant brand recognition and market share. The company is actively diversifying its portfolio to mitigate future patent expirations.
↑Robust R&D Pipeline
A consistent investment in research and development fuels a pipeline of innovative drugs. This allows AbbVie to address unmet medical needs and secure future revenue streams.
↑Neuroscience Growth Drivers
The neuroscience franchise is demonstrating strong operational sales growth, exceeding expectations. This segment is becoming an increasingly important contributor to AbbVie's overall performance.
INVESTMENT RISKS
↓Regulatory Scrutiny and Pricing Pressures
The pharmaceutical industry faces ongoing regulatory oversight and political pressure regarding drug pricing. Changes in policy could impact profitability and market access.
↓Clinical Trial Failures
The success of drug development is inherently uncertain. A significant failure in late-stage clinical trials for a key pipeline candidate could severely impact future growth.
↓Integration of Acquisitions
AbbVie's growth strategy often involves acquisitions. The successful integration of these companies and their products is crucial for realizing their full value.
Base case
Intrinsic Value
$287.27
Margin of safety
+0.4%
Expected annual return
+0.1%
Base case assumptions: 7.9% annual earnings growth, 49.01x target PE, 10% discount rate, 5 year projection. Data as of 2026-11-20.
This base case uses default assumptions and is not financial advice. The fair value changes significantly when the target PE or earnings growth rate changes. Open the calculator to set your own assumptions and see the full sensitivity range.
Adjust the target PE, earnings growth, and discount rate to see how the fair value and margin of safety for AbbVie Inc. respond.
Open PE Calculator for ABBVAbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
PE Ratio (TTM)
49.1x
PEG Ratio
0.15
Earnings Yield
2.04%
ROE (TTM)
-202.3%
Revenue/Share (TTM)
$37.25
Dividend Yield
2.42%
Debt/Equity
n/m
The trailing twelve-month PE ratio of ABBV reflects how much investors pay per dollar of AbbVie Inc.'s earnings. This metric is most useful when compared to Drug Manufacturers - General peers and the company's own historical range.
ABBV's PE of 49.1x combined with a PEG ratio of 0.15 provides a growth-adjusted perspective. A PEG below 1.0 means the P/E is low relative to the earnings growth rate. Keep in mind that PE-based valuation works best for profitable, mature companies — for high-growth or cyclical Drug Manufacturers - General, a DCF analysis may be more appropriate.
To value AbbVie Inc. using PE: (1) Compare the current PE (49.1x) against the Drug Manufacturers - General median to assess relative pricing, (2) check the PEG ratio (0.15) to adjust for growth expectations, (3) review the 5-year PE range to identify where the stock sits historically, and (4) estimate fair value by multiplying a target PE by forward EPS estimates. This relative approach complements DCF's absolute valuation.
ABBV's PEG ratio is 0.15, calculated by dividing the PE ratio (49.1x) by the expected earnings growth rate. A PEG below 1.0 means the P/E is low relative to the expected earnings growth rate. Note that PEG accuracy depends on the reliability of growth estimates.
PE ratio gives a quick relative read — how ABBV is priced versus Drug Manufacturers - General peers. DCF provides an absolute value based on projected free cash flows. For the most reliable valuation, use PE as a quick comparability screen and DCF for a deeper fundamental analysis. Each method has blind spots: PE ignores capital structure and cash flow quality, while DCF is sensitive to growth and discount rate assumptions.
P/E and DCF value ABBV with different methods and assumptions, so the two conclusions can differ. Compare the DCF intrinsic value.
Price as of 2026-11-20. Financial data from Financial Modeling Prep (trailing twelve months) · Valuation methodology by Charlie Wang.
This is an estimate, not investment advice.